Cell Bio Human Tech Co Ltd

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.36, below the median for the Textiles & Leather Goods industry. It holds 15.9 billion KRW in cash and equivalents, but net cash is negative after subtracting long-term debt of 20.5 billion KRW. Free cash flow of 3.9 billion KRW indicates modest liquidity, though the current ratio of 2.29 suggests short-term obligations are well-covered. Profitability metrics show strong performance, with a return on equity of 15.37% and return on assets of 9.86%, both exceeding the industry median. Gross margin of 36.9% (18.8 billion KRW gross profit on 51.1 billion KRW revenue) reflects efficient production, though operating margin of 19.3% (9.8 billion KRW operating income) suggests moderate overhead pressures. Revenue is concentrated in a single product line—eco-friendly mask pack materials—accounting for the majority of sales. Geographic exposure is limited to Korea, with no disclosed international operations. This concentration increases vulnerability to domestic demand shifts and regulatory changes. Outlook for the current fiscal year shows revenue growth of 4.2% year-over-year, with a 3.1% increase in operating income. Capital expenditure of -6.8 billion KRW indicates asset disposals or reduced investment in production capacity. The next fiscal year is projected to see a 2.8% revenue decline, driven by market saturation in the mask pack segment. Risk assessment highlights liquidity as a medium concern due to negative net cash, though dilution risk is low. No recent equity issuances or ATM programs are disclosed, and shares outstanding remain unchanged between basic and diluted counts. Adjustments to valuation metrics reflect conservative debt assumptions. Recent filings and transcripts show no material changes in business strategy or product pipeline. The company continues to focus on eco-friendly materials and has no disclosed R&D projects beyond incremental improvements to existing product lines.